NIH Funding Opportunities
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 40 min ago
Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award, (U01 Clinical Trial Optional)
Funding Opportunity PAR-19-099 from the NIH Guide for Grants and Contracts. The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop innovative solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support investigators from three or more CTSA Program hub institutions (see below under Eligible Individuals) to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to address the purpose of this FOA.
Funding Opportunity PAR-19-102 from the NIH Guide for Grants and Contracts. The goal of the Graduate Research Initiative for Student Enhancement (G-RISE) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-active institutions (i.e., those with a 3-year average of NIH Research Project Grant funding less than $7.5 million total costs).
Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U01 Clinical Trial Optional)
Funding Opportunity PAR-19-101 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the PS-OPs is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming small transdisciplinary teams of physical scientists and cancer biologists/physician-scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.
Notice of Intent to Publish a Funding Opportunity Announcement for Administrative Supplements for Research on Bioethical Issues
Notice NOT-OD-19-045 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-023 from the NIH Guide for Grants and Contracts
NHLBI accepts investigator-initiated basic experimental studies involving humans (BESH) that meet NIHs definition of a clinical trial only in response to PA-18-345 NIH Research Project Grant (Parent R01 Clinical Trial Required)
Notice NOT-HL-18-663 from the NIH Guide for Grants and Contracts
NHLBI Accepts Only Investigator-Initiated Clinical Trial Applications Proposing Mechanistic Studies and Basic Experimental Studies Involving Humans (BESH) in Response to the NIH Parent R01 Clinical Trial Required Announcement
Notice NOT-HL-18-662 from the NIH Guide for Grants and Contracts
Center without Walls for PET Ligand Development for Alzheimer's disease related dementias (ADRDs) (U19 Clinical Trial Optional)
Funding Opportunity RFA-NS-19-014 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for development of new compounds and improvement of existing ligand specificity and selectivity, initial screening of ligands in appropriate animal models, and radioligand formulation and first-in-human testing. The Center without Walls should encompass research that will move promising ligands through in vitro and in vivo optimization to first-in-human studies. Applications must include an administrative core, a medicinal chemistry core, a clinical core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.
Funding Opportunity PAR-19-098 from the NIH Guide for Grants and Contracts. This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.
NHLBI Announces Participation in RFA-OD-19-013 "Specialized Centers of Research Excellence (SCORE) on Sex Differences (U54 Clinical Trial Optional)"
Notice NOT-HL-18-669 from the NIH Guide for Grants and Contracts
Notice of NIBIB's Participation in PA-18-817 "Administrative Supplements for Research on Dietary Supplements (Admin Supp - Clinical Trial Not Allowed)"
Notice NOT-EB-18-034 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-668 from the NIH Guide for Grants and Contracts
Notice of Changes in the Eligibility of Candidates and Budget Supported by the NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical training (Admin Supp)
Notice NOT-MH-18-074 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AA-19-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeksl applications for a research center grant to conduct cross-cutting research on alcohol and HIV/AIDS. Through this FOA, NIAAA seeks to encourage research that can be translated into interventions in order to reduce infection and transmission of HIV. The FY2013 Trans-NIH Plan For HIV-Related Research (http://www.oar.nih.gov/strategicplan/fy2013/index.asp) describes the goals of highest priority.
Notice of Information: NIMH Priorities for Research to Inform Stepped-Care Interventions for Persons at Clinical High Risk for Psychosis
Notice NOT-MH-19-003 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-040 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-041 from the NIH Guide for Grants and Contracts
Notice of Change to PAR-18-319 "HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)"
Notice NOT-AI-19-016 from the NIH Guide for Grants and Contracts
HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required)
Funding Opportunity RFA-DA-19-035 from the NIH Guide for Grants and Contracts. This FOA is intended to solicit two-phase research applications to develop, adapt and test interventions and strategies to prevent initiation of opioid misuse and development of OUD in at-risk older adolescents and young adults (ages 16-30). The goal is to stimulate research studies conducted in populations and geographic areas most affected by the opioid crisis or with indicators of an emerging crisis. Of priority are studies that target older adolescents and young adults in health care settings (including primary care, surgical, orthopedic and other specialty care, dental care, emergency departments, urgent care, HIV/STI and reproductive health clinics, prenatal clinics, school-based health centers, federally qualified health centers, military medicine settings, occupational health settings), justice settings (including criminal justice, juvenile justice, as well as child welfare and other systems that cross with the justice system) and other systems and settings. Studies that include understudied at-risk older adolescent and young adult populations are strongly encouraged. Examples include, but are not limited to individuals in rural or reservation settings, women, veterans, and individuals with a history of polysubstance use or mental disorders.
HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Funding Opportunity RFA-NS-19-021 from the NIH Guide for Grants and Contracts. The Purpose of this FOA is to solicit cooperative agreement applications that propose clinical trials to establish the effectiveness of existing therapies and approaches for prevention and management of pain. The studies must address questions within the mission and research interests of participating NIH Institutes and Centers and evaluate preventive strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, diagnostic testing, behavioral change, rehabilitation strategies, complementary therapies, integrated approaches, and delivery system strategies in well controlled trials The overall goal is to inform clinicians about the effectiveness of interventions that will improve functional outcomes and reduce pain across the continuum of acute to chronic pain associated with many types of diseases or conditions or pain presenting as a disease itself. Clinical trials will be conducted within the infrastructure of the HEAL Pain Management Effectiveness Research Network.
NIH Funding Opportunities
- Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
- Using Data Analytics to Support Primary Care and Community Interventions to Improve Chronic Disease Prevention and Management and Population Health (R18)
- Behavioral and Social Research to Address Health Disparities in the U.S. (Admin Supp Clinical Trial Optional)
- NICHD Data and Specimen Hub (DASH) Releases New Functionality for Biospecimen Requests
- Notice of Change in the Number of Trainee Slots on NHGRI T32 Postdoctoral Training Program in Genomic Medicine Research